Receive our newsletter – data, insights and analysis delivered to you
December 9, 2012

Phoenix Children’s Hospital forms paediatric institute of molecular medicine

Phoenix Children's Hospital in the US has formed a new institute, the Ronald A. Matricaria Institute of Molecular Medicine, to provide genomic analysis and drugs access to paediatric patients.

By admin-demo

Phoenix Children’s Hospital in the US has formed a new institute, the Ronald A. Matricaria Institute of Molecular Medicine, to provide genomic analysis and drugs access to paediatric patients.

The new institute will carry out clinical studies in children for better understanding of the specific differences between children and adults, resulting in the development of safe, effective and age-suitable treatments.

"Research and development of novel treatments for paediatric diseases has fallen short over past decades."

Phoenix Children’s president and CEO Robert Meyer said the objective of the institute is to bring genomics research to the forefront of paediatrics.

"Research and development of novel treatments for paediatric diseases has fallen short over past decades," Meyer added.

"We also must address a fundamental flaw in traditional and personalised medicine – diagnosis and treatment of a disease based on clinical instead of genomic information."

By studying the patient’s genetic makeup, researchers will be able to identify the individual’s susceptibility to disease and response to specific drugs.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

The institute will initially focus on paediatric cancers and later expand to other paediatric disease research.

The University of Arizona College of Medicine will bring academic and research programmes, in addition to the academic credentials needed to develop a research programme, while Translational Genomics Research Institute will contribute expertise in genomics and bioinformatics, as well as sophisticated laboratory space.

"Our collaboration with TGen and University of Arizona opens the doors to making a portfolio of drugs and compounds available immediately," Meyer added.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU